Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) Infection

About Hepatitis D Virus (HDV)HDV is the most severe form of viral hepatitis and occurs only in individuals co-infected with hepatitis B virus (HBV). HDV accelerates liver disease progression, significantly increasing the risk of cirrhosis, liver failure, and hepatocellular carcinoma. It is estimated that 12–20 million people globally are affected by HDV, with limited therapeutic options currently available. About Hepatitis D Virus (HDV)HDV is the most severe form of viral hepatitis and...

About Hepatitis D Virus (HDV)
HDV is the most severe form of viral hepatitis and occurs only in individuals co-infected with hepatitis B virus (HBV). HDV accelerates liver disease progression, significantly increasing the risk of cirrhosis, liver failure, and hepatocellular carcinoma. It is estimated that 12–20 million people globally are affected by HDV, with limited therapeutic options currently available.

Despite its severity, HDV remains underdiagnosed and underserved. The development of targeted therapies like RBD1016 offers a promising path forward for patients and clinicians seeking more effective and durable treatment options.

About Ribo

Suzhou Ribo Life Science Co. Ltd. is a pioneer in advancing RNAi technology and industrialization of oligonucleotide drugs in China, has established an oligonucleotide therapeutic platform that vertically integrates the complete set of technologies and has built a globally integrated drug development capability and a rich siRNA pipeline.

Ribocure Pharmaceuticals AB is Ribo's international R&D center established in Gothenburg, Sweden.

For more information please visit www.ribolia.com & www.ribocure.com.

Logo - https://mma.prnewswire.com/media/2804420/logo_Ribolia_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/ribo-granted-ema-orphan-drug-designation-for-sirna-therapeutic-rbd1016-for-hepatitis-delta-virus-hdv-infection-302593812.html